Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.
Journal
Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004
Informations de publication
Date de publication:
18 Jan 2019
18 Jan 2019
Historique:
received:
04
09
2018
accepted:
20
12
2018
revised:
23
11
2018
entrez:
20
1
2019
pubmed:
20
1
2019
medline:
20
1
2019
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stromal reaction (desmoplasia). We have previously reported that mice with conditional Kras
Identifiants
pubmed: 30659170
doi: 10.1038/s41389-018-0117-8
pii: 10.1038/s41389-018-0117-8
pmc: PMC6338726
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Références
Pancreas. 1999 Nov;19(4):370-6
pubmed: 10547197
J Immunol. 1999 Dec 1;163(11):6086-94
pubmed: 10570298
Anticancer Res. 2000 Jan-Feb;20(1A):43-51
pubmed: 10769633
J Invest Dermatol. 2000 Aug;115(2):234-44
pubmed: 10951241
Am J Surg Pathol. 2001 May;25(5):579-86
pubmed: 11342768
J Immunol. 2001 Dec 1;167(11):6503-9
pubmed: 11714818
Nat Rev Cancer. 2002 Dec;2(12):897-909
pubmed: 12459728
J Clin Invest. 2002 Dec;110(11):1703-16
pubmed: 12464676
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
J Immunol. 2004 Mar 1;172(5):2853-60
pubmed: 14978086
J Immunol. 2004 Mar 15;172(6):3860-8
pubmed: 15004193
Eur J Cancer. 2006 Apr;42(6):768-78
pubmed: 16510280
Genes Dev. 2006 Nov 15;20(22):3147-60
pubmed: 17114585
N Engl J Med. 1992 Feb 13;326(7):455-65
pubmed: 1732772
Cancer Lett. 2008 Aug 28;267(2):226-44
pubmed: 18579287
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Int J Cancer. 2009 Sep 1;125(5):1027-37
pubmed: 19431209
Mol Cancer Res. 2009 Jun;7(6):799-808
pubmed: 19509115
Am J Pathol. 2010 Nov;177(5):2585-96
pubmed: 20934972
Eur J Immunol. 2010 Nov;40(11):2969-75
pubmed: 21061430
J Clin Invest. 2011 Oct;121(10):4106-17
pubmed: 21926469
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
PLoS One. 2013 May 27;8(5):e63967
pubmed: 23724011
J Cell Biol. 2013 Aug 5;202(3):563-77
pubmed: 23918941
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Oncotarget. 2016 Sep 20;7(38):61469-61484
pubmed: 27528027
Neoplasia. 2016 Dec;18(12):785-794
pubmed: 27889647
Oncogenesis. 2016 Dec 12;5(12):e277
pubmed: 27941932
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Sci Rep. 2017 Feb 16;7:42681
pubmed: 28205614
Cancer Lett. 2017 Jul 1;397:72-82
pubmed: 28347789
Oncotarget. 2017 Jul 18;8(29):48436-48452
pubmed: 28467800
J Biol Chem. 1995 Nov 10;270(45):27348-57
pubmed: 7592998
Cancer Res. 1997 May 1;57(9):1731-4
pubmed: 9135016